Esperion Therapeutics, Inc.
METHODS FOR REDUCING THE RISK OF DIABETES IN PATIENTS BEING TREATED FOR HIGH CHOLESTEROL-RELATED ILLNESSES

Abstract:

Disclosed herein are compositions comprising fixed doses of ETC-1002, ezetimibe, and statin, and methods of treating subjects comprising administering fixed doses of ETC-1002, ezetimibe, and statin. Also disclosed herein are methods for administering fixed doses of ETC-1002 or ezetimibe or both to statin-intolerant patients or patients receiving statin therapy, wherein the administration reduces the likelihood of worsening diabetes in the subject or increasing the likelihood of new onset diabetes in a subject. The methods disclosed herein also include methods of treating hypercholesterolemia and cardiovascular diseases in a subject.